Langerhans cell histiocytosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: All the following criteria must be met: 1. Patients were diagnosed as LCH by clinical and pathological examination from May 2020 to December 2025; 2. Two or more organs or systems were involved, and no dangerous organs (liver, spleen, hematopoietic system) were involved at diagnosis; 3. Patients were not treated by any anti-tumor treatment before diagnosis; 4. Patients were less than 18 years of age; 5. Informed consent were obtained from guardians of the patients and the patients (more than 8 years old).
Exclusion criteria
Exclusion criteria: If one of the following conditions exists, he/she will not be included in this study: 1. Patients who can't carry out systematic treatment according to the standardized diagnosis and treatment protocol; 2. Patients who can't carry out the treatment according to the established protocol due to personal reasons during the treatment; 3. Those who have any significant abnormal coexisting diseases or mental diseases that affect the life safety and compliance of patients, and informed consent, research participation, follow-up or result interpretation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival;Progression-free Survival;Cumulative incidence of relapse;Cumulative incidence of permanent consequences; | — |
Secondary
| Measure | Time frame |
|---|---|
| 6-week response rate;6-week response rate;Hazard ratio;Overall survival;Tissue BRAF mutations;cell-free BRAF mutations;Dynamic changes of key biomarkers during treatment;Adverse events; | — |
Countries
China
Contacts
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health